The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis

Ian Wright, Andrea Civitarese, Richard Baverstock

Abstract


The use of intra-detrusor onabotulinumtoxinA (Botox®) in patients with myasthenia gravis has not been reported, and little evidence exists to substantiate a complete contraindication of Botox use in this population. Here, we present two cases of comorbid overactive bladder (OAB) and myasthenia gravis successfully treated with intra-detrusor Botox.

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.5489/cuaj.3678

Comments on this article

View all comments
 |  Add comment